HOME › DRUGS › RETEPLASE
ACTIVE SUBSTANCE / INN

RETEPLASE

Brand name(s): Ecokinase, Rapilysin, RETAVASE
FDA LISTED
EMA LISTED
PRESCRIPTION
WITHDRAWN
AUTHORISED
BLA103786
Myocardial Infarction
ACTIVE SUBSTANCE
Reteplase
REGULATORS
FDA · EMA
SPONSORS / MAH
EKR THERAP, Actavis Group PTC ehf, Roche Registration Ltd.
TOTAL APPLICATIONS
3
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
RETAVASEBLA103786EKR THERAPPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
RapilysinActavis Group PTC ehfAuthorised29/08/1996Myocardial Infarction
EcokinaseRoche Registration Ltd.Withdrawn29/08/1996Myocardial Infarction

FULL INTELLIGENCE ON RETEPLASE

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →